StockData

Arrowhead Pharmaceuticals vs Travere Therapeutics

ARWR and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARWR and TVTX compare

Arrowhead Pharmaceuticals is the larger company, worth 1.3 times as much as Travere Therapeutics ($6.1B against $4.8B).

Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus 16.8% for Arrowhead Pharmaceuticals).

Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −7.4% compared with −47.8% at Arrowhead Pharmaceuticals.

Travere Therapeutics scores higher on the StockData Score (6 against 5 for Arrowhead Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARWRTVTX
Size and price
Market cap$6.1B$4.8B
Share price$42.99$51.10
Change, 1 year4.2%48.1%
Change, 5 years−40.3%76.0%
Beta (5Y)1.571.91
Employees711497
StockData Score
Total score56 (better)
Valuation score00
Growth score23 (better)
Performance score22
Health score11
Dividend score00
Valuation
P/S9.1×8.1× (better)
P/B13.0× (better)196×
EV/EBITDA–197×
FCF yield−1.2%–
Fair value$31.89$6.01
Margin of safety−34.8% (better)−751%
Growth
Revenue growth (TTM)16.8%77.1% (better)
Revenue growth, 5Y average56.6% (better)19.9%
Profitability
Gross margin–98.6%
Operating margin−33.8%−6.8% (better)
Net margin−47.8%−7.4% (better)
FCF margin−11.2%–
Return on equity−64.8% (better)−152%
Financial health
Interest coverage−2.4× (better)−4.3×
Current ratio5.90 (better)4.05
Altman Z-score1.692.29 (better)
Piotroski F-score57 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions84.6%112%
Held by insiders4.0%1.6%
Insider net buying, 12 months−$36.9M (better)−$110M
Short interest, % of float8.5%10.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.